EUVIMEDEUVIMED entdecken
Open Access

Regulation of AUF1 alternative splicing by hnRNPA1 and SRSF2 modulate the sensitivity of ovarian cancer cells to cisplatin

Jia-Mei Wang, Ning Liu, Xue-Jing Wei, Fu-Ying Zhao, Chao Li, Hua-Qin Wang, Chuan Liu

Cellular Oncology · 2024

DOI: 10.1007/s13402-024-01023-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cellular Oncology, 2024. Verfasst von Jia-Mei Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Laboratory Medicine, Department of Laboratory Medicine, The First Hospital of China Medical University, Shenyan…. Hauptthemen laut MEDLINE: Heterogeneous Nuclear Ribonucleoprotein A1, Ovarian Neoplasms, Serine-Arginine Splicing Factors, Cisplatin. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Clarification of cisplatin resistance may provide new targets for therapy in cisplatin resistant ovarian cancer. The current study aims to explore involvement of isoforms of AU-rich element RNA-binding protein 1 (AUF1) in cisplatin resistance in ovarian cancer. METHODS: The cancer stem cell-like features were analyzed using colony formation assay, tumor sphere formation assay and nude mouse xenograft experiments. AUF1 isoforms expression was analyzed using immunoblotting, qRT-PCR, and immunohistochemistry. RIP and Biotin pulldown was used to analyze the interaction of SRSF2 and hnRNPA1 with AUF1 transcript. Transcriptome regulated by AUF1 isoforms was analyzed by RNA-seq. RESULTS: The current study demonstrated differential expression of AUF1 isoforms in cisplatin sensitive and resistant ovarian cancer tissues and cells. P37 isoform promoted proliferation, while p45 isoform enhanced responsiveness of ovarian cancer cells to cisplatin. the clonal formation capacity of the cells, and the restoration of p45 expression reduced the capacity with cisplatin treatment. The competitive binding of phosphorylated hnRNPA1 and O-GlcNAc-modified SRSF2 on AUF1 exon 2 and exon 7 regulated the alternative splicing of AUF1. CONCLUSION: The competitive binding of phosphorylated hnRNPA1 and O-GlcNAc modified SRSF2 on exon 2 and exon 7 regulated the alternative splicing of AUF1 and subsequent isoform expression. P37 isoform played a "cancer promoter" role, p42 and p45, especially p45 played a "cancer suppressor" role in ovarian cancer. This study provides a new target for exploring the drug resistance mechanism of ovarian cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heterogeneous Nuclear Ribonucleoprotein A1Ovarian NeoplasmsSerine-Arginine Splicing FactorsCisplatinAlternative SplicingMice, NudeDrug Resistance, NeoplasmHumansFemaleCell Line, TumorAnimalsGene Expression Regulation, NeoplasticMiceProtein IsoformsCell ProliferationXenograft Model Antitumor AssaysMice, Inbred BALB CHeterogeneous-Nuclear Ribonucleoprotein Group A-BAntineoplastic Agents

Stichwörter der Autor:innen

AU-rich element RNA-binding protein 1 (AUF1)Alternative splicingCisplatinOvarian cancer

Substanzen

Heterogeneous Nuclear Ribonucleoprotein A1Serine-Arginine Splicing FactorsCisplatinSRSF2 protein, humanhnRNPA1 protein, humanProtein IsoformsHeterogeneous-Nuclear Ribonucleoprotein Group A-BAntineoplastic Agents

Autor:innen und Institutionen

  • National Clinical Research Center for Laboratory Medicine, Department of Laboratory Medicine, The First Hospital of China Medical University, Shenyang, 110001, China.
  • Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
  • Department of Biochemistry and Molecular Biology, China Medical University, Shenyang, 110026, China.
  • Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, 110004, China. liuc@sj-hospital.org.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wang, J. M., Liu, N., Wei, X. J., Zhao, F. Y., Li, C., Wang, H. Q., & Liu, C. (2024). Regulation of AUF1 alternative splicing by hnRNPA1 and SRSF2 modulate the sensitivity of ovarian cancer cells to cisplatin. Cellular Oncology. https://doi.org/10.1007/s13402-024-01023-8

Vancouver

Wang JM, Liu N, Wei XJ, Zhao FY, Li C, Wang HQ, et al. Regulation of AUF1 alternative splicing by hnRNPA1 and SRSF2 modulate the sensitivity of ovarian cancer cells to cisplatin. Cellular Oncology. 2024. doi:10.1007/s13402-024-01023-8

BibTeX
@article{Wang2024,
  author = {Wang, Jia-Mei and Liu, Ning and Wei, Xue-Jing and Zhao, Fu-Ying and Li, Chao and Wang, Hua-Qin and Liu, Chuan},
  title = {Regulation of AUF1 alternative splicing by hnRNPA1 and SRSF2 modulate the sensitivity of ovarian cancer cells to cisplatin},
  journal = {Cellular Oncology},
  year = {2024},
  doi = {10.1007/s13402-024-01023-8}
}
Kostenlos starten →